282 related articles for article (PubMed ID: 12130585)
1. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.
Shimada T; Muto T; Urakawa I; Yoneya T; Yamazaki Y; Okawa K; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Endocrinology; 2002 Aug; 143(8):3179-82. PubMed ID: 12130585
[TBL] [Abstract][Full Text] [Related]
2. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.
White KE; Carn G; Lorenz-Depiereux B; Benet-Pages A; Strom TM; Econs MJ
Kidney Int; 2001 Dec; 60(6):2079-86. PubMed ID: 11737582
[TBL] [Abstract][Full Text] [Related]
3. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.
White KE; Jonsson KB; Carn G; Hampson G; Spector TD; Mannstadt M; Lorenz-Depiereux B; Miyauchi A; Yang IM; Ljunggren O; Meitinger T; Strom TM; Jüppner H; Econs MJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):497-500. PubMed ID: 11157998
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
5. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S; Yamashita T
Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
[TBL] [Abstract][Full Text] [Related]
9. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
10. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.
Bai XY; Miao D; Goltzman D; Karaplis AC
J Biol Chem; 2003 Mar; 278(11):9843-9. PubMed ID: 12519781
[TBL] [Abstract][Full Text] [Related]
11. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
12. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
13. FGF23 and disorders of phosphate homeostasis.
Yu X; White KE
Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
[TBL] [Abstract][Full Text] [Related]
15. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.
ADHR Consortium
Nat Genet; 2000 Nov; 26(3):345-8. PubMed ID: 11062477
[TBL] [Abstract][Full Text] [Related]
16. [Hereditary hypophosphatemia in adults].
Vélayoudom-Céphise FL; Vantyghem MC; Wémeau JL
Presse Med; 2005 Dec; 34(22 Pt 1):1720-6. PubMed ID: 16374396
[TBL] [Abstract][Full Text] [Related]
17. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
Menon LP; Weinstein RS
Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
[TBL] [Abstract][Full Text] [Related]
18. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
[TBL] [Abstract][Full Text] [Related]
19. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
20. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
